ClinicalTrials.gg
CompletedNCT00431522Updated May 29, 2009

Valproic Acid Sodium Salt in Bipolar Disorder

A Phase 4 interventional study of Valproic acid, sodium salt in Bipolar Disorder, sponsored by Sanofi. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-05-29.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Valproic Acid in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Valproic Acid · Bipolar Disorder.

Enrollment
21st of 41
58 · median 58
Started
2004
with 10 others
Phase 4
20 of 41
none open now
Registered
26th of 41
by date
Lead sponsor
3 of 41
Sanofi

Among the 41 studies testing Valproic Acid in Bipolar Disorder, this one is the 21st largest by enrollment, is one of 11 that started in 2004, is one of 20 in phase 4, and was the 26th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 41 studies testing Valproic Acid in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing Valproic Acid in Bipolar Disorder as a file.
02

Study summary

  • To determine the total and local gray matter volumes, and N-acetyl aspartate (NAA) levels in patients with bipolar disorders who are within euthimic, depressive or manic/hypomanic period and who are not taking drug;
  • To investigate the neuroprotective effects of long-term (6 weeks) use of valproate on total and local gray matter volumes and NAA levels.
  • To measure the brain electrical response to visual and auditory impulses before and after valproate treatment in patients within euthimic, depressive or manic/hypomanic period and who are not taking drug, and to compare the data with each other and with normal groups.
  • To determine the cognitive functions before and after the valproate treatment in the same patient group, to compare the data with each other and with age- and sex-paired normal controls;
  • To determine the relationship between these effects of valproate and clinical improvement;
  • To investigate the relationship between cognitive ability status and electrical activity of brain, to compare this with that in control group; to determine the relationship between the data and brain imaging (MRI/MRS) findings in conjunction with localization
03

Conditions studied

  • Bipolar Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of type I or II bipolar disorder according to after stratified SCID I interview,
  • being currently euthimic (for at least one month), manic-hypomanic and having YMRS points of 15 or more, or being in depressive episode and having HAM-D21 points of 15 or more
  • being not taking drugs for at least two weeks before participating in the study (except benzodiazepins)

Exclusion criteria

Exclusion Criteria:

  • female who are pregnant or planning to be pregnant, nursing
  • having known to study drug
  • being given any psychotropic agent other than benzodiazepine within the last two weeks
  • active sustance or alcohol usage within the last two weeks, or substance addiction other than cafein or nicotine (within the last month)
  • having another axis I disorder such as comorbid dementia, delirium, obsessive compulsive disorder, eating disorder
  • having unstabilised hepatic or renal disorder, thyroid or blood disease
  • having history of cerebral surgery
  • existence of a degenerative neurologic disease or epilepsy
  • having pacemaker
  • having a prosthesis able to magnetic effect in eye, brain or sites near to these regions
  • homicide thougths or severe catatonia required to be hospitalized
  • having mixed episode

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
58 participants (actual)
06

What researchers measure

Primary outcomes

  1. To assess regional N-acetyl aspartate (NAA) levels in drug free bipolar patients either in manic/hypomanic, or depressive or euthymic state

    Time frame: for 6 weeks

  2. To investigate valporate's effect on total and regional gray matter volume and NAA levels;

    Time frame: for 6 weeks

Secondary outcomes

  1. To assess evoked and event related potentials to visual and auditory stimuli in patients before and after valproate monotherapy in comparison to healthy controls

    Time frame: for 6 weeks

  2. To determine the relationship between clinical improvement and image data changes in depressed or manic/hypomanic patients,

    Time frame: for 6 weeks

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2007
First posted
Feb 5, 2007
Start
Dec 2004
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Last update
May 29, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00431522
Lead sponsor
Sanofi
First posted
Feb 5, 2007
Start date
Dec 2004
Primary completion
Oct 2006
Completion
Oct 2006
Last update
May 29, 2009

Study contacts

Edibe Taylan
study director · Sanofi-aventis Turkey
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion